Thyroid eye disease
Conditions
Brief summary
≥2 point reduction in Clinical Activity Score (CAS) from baseline at week 12.
Detailed description
≥ 2 mm reduction from baseline in proptosis in one eye at week 12., ≥ 2 mm reduction from baseline in vertical lid aperture in one eye at week 12., ≥ 1 class improvement of eye motility from baseline assessed by Gorman score at week 12., Gorman score: 1 = no diplopia, 2 intermittent diplopia, 3 = inconstant (gaze-evoked) diplopia, 4 = constant diplopia in primary or reading position, ≥ 6 points improvement in GO-QOL score
Interventions
DRUGSolu-Medrol S.A.B. (Sine Alcohol Benzylicus) 500 mg Pulver und Lösungsmittel zur Herstellung einer Injektionslösung Methylprednisolon
Sponsors
Helse Bergen HF
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ≥2 point reduction in Clinical Activity Score (CAS) from baseline at week 12. | — |
Secondary
| Measure | Time frame |
|---|---|
| ≥ 2 mm reduction from baseline in proptosis in one eye at week 12., ≥ 2 mm reduction from baseline in vertical lid aperture in one eye at week 12., ≥ 1 class improvement of eye motility from baseline assessed by Gorman score at week 12., Gorman score: 1 = no diplopia, 2 intermittent diplopia, 3 = inconstant (gaze-evoked) diplopia, 4 = constant diplopia in primary or reading position, ≥ 6 points improvement in GO-QOL score | — |
Countries
Norway
Outcome results
None listed